Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | ARG1 | P05089 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8103404 | 0.84 | GABRP (0.41) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7364076 | 0.81 | GABRP (0.38) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29115925 | 0.79 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL19815863 | 0.79 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30661793 | 0.79 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL17747395 | 0.78 | TSHR (0.42) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7474652 | 0.75 | CHRNB2 (0.33) | — | |
| SCHEMBL6026414 | 0.72 | SIGMAR1 (0.36) | ARG1CYP1A2ALOX15CYP2C19MEN1 | |
| SCHEMBL20726260 | 0.72 | AGL (0.35) | — | |
| SCHEMBL30876713 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0823254-B1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-0497258-B1 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6303624-B1 | PREVENTION AND/OR TREATMENT OF HYPERPHOSPHATEMIA OR SECONDARY HYPERPARATHYROIDISM, INCLUSIVE OF ACCESSORY DISORDERS BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6232324-B1 | AS HYPERTENSIVE AGENTS FOR DIALYSIS INDUCED HYPOTENSION; ADMINISTERING COMPOUNDS SUCH AS 1-(3-(2-PHENYLPYRAZOLO(1,5-A) PYRIDIN-3-YL)ACRYLOYL)-2-(CARBOXY METHYL)PIPERIDINE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| EP-1084710-A1 | REMEDIES FOR MALE STERILITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0972525-A1 | PREVENTIVES AND REMEDIES FOR HYPERPHOSPHATEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5296490-A | Pharmaceutically useful pyrazolopyridines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| US-5179103-A | Diuretics, hypotensive agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | TSHR 601/4885GABRP 633/4885GABRD 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.